Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 7
1992 32
1993 40
1994 23
1995 19
1996 21
1997 20
1998 53
1999 127
2000 181
2001 322
2002 412
2003 523
2004 757
2005 1091
2006 1430
2007 1884
2008 2380
2009 2856
2010 3323
2011 3790
2012 4218
2013 4455
2014 4512
2015 2757
2016 2244
2017 2656
2018 2784
2019 1484
2020 38
Text availability
Article attribute
Article type
Publication date

Search Results

39,093 results
Results by year
Filters applied: . Clear all
Page 1
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
Pittock SJ, et al. N Engl J Med 2019 - Clinical Trial. PMID 31050279
At least two thirds of cases are associated with aquaporin-4 antibodies (AQP4-IgG) and complement-mediated damage to the central nervous system. ...
At least two thirds of cases are associated with aquaporin-4 antibodies (AQP4-IgG) and complement-mediated damage to the central nerv …
Status of PCSK9 Monoclonal Antibodies in Australia.
Scherer DJ, et al. Heart Lung Circ 2019 - Review. PMID 31104887
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. ...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lip …
[Monoclonal antibodies for severe asthma (review)].
Solèr M. Ther Umsch 2019 - Review. PMID 31762416 German.
Monoclonal antibodies for severe asthma (review) Abstract. Monoclonal antibodies against central steps in the inflammatory cascade of bronchial asthma offer welcome new treatment options for a selected group of patients with severe asthma. ...
Monoclonal antibodies for severe asthma (review) Abstract. Monoclonal antibodies against central steps in the inflammatory cas …
Safety of selective IL-23p19 inhibitors for the treatment of psoriasis
Crowley JJ, et al. J Eur Acad Dermatol Venereol 2019 - Review. PMID 31054215 Free PMC article.
The monoclonal antibodies tildrakizumab, guselkumab and risankizumab target the p19 subunit that is specific to interleukin (IL)-23. ...
The monoclonal antibodies tildrakizumab, guselkumab and risankizumab target the p19 subunit that is specific to interleukin (IL)-23. …
39,093 results
Jump to page
Feedback